Abstract
Background: In response to the COVID-19 pandemic, the CDC issued guidance advising patients and providers to adopt social distancing practices such as home-based infusions (H-BI).
Methods: We performed a mixed methods evaluation to summarize perceptions, concerns, and experiences with H-BI among all inflammatory bowel disease patients 18-90 years of age who transitioned to home-based infliximab or vedolizumab infusions between March to July 2020 at a tertiary care center. Semi-structured interviews were conducted and analyzed using an iterative, inductive thematic approach. Baseline characteristics and outcome on safety, COVID-19 transmission, delays in infusions, and H-BI persistence were collected.
Results: Of the 57 participants who transitioned to H-BI, 20 (33%) responded. Four major categories and six major themes related to expectations, experience, perceived safety, and logistical factors were identified. Initial perceptions were mixed, however these resolved. One patient developed COVID-19, one patient experienced an adverse event, 12 (21%) patients experienced an infusion delay, and 6 (11%) patients transitioned from H-BI.
Discussion: Despite mixed initial perceptions, respondents had a positive experience with most respondents planning to continue H-BI after the pandemic resolves. Several real-world actionable barriers were identified related to scheduling, communication between stakeholders, and nursing quality. No major safety concerns were identified.
Keywords: Biologics; COVID-19; Inflammatory bowel disease; Infusions.
【저자키워드】 COVID-19, biologics, Inflammatory bowel disease, Infusions., 【초록키워드】 pandemic, social distancing, COVID-19 pandemic, outcome, Characteristics, CDC, persistence, adverse event, Patient, age, Care, Guidance, COVID-19 transmission, Factor, one patient, participant, positive, bowel, approach, initial, analyzed, performed, collected, conducted, category, iterative, resolved, transitioned, 【제목키워드】 COVID-19 pandemic, Patient, disease, bowel,